Division of Eisai Co. Ltd.
Latest From Eisai Inc.
Coronavirus Update: More Companies Join Therapeutics Accelerator, FDA Delays AdCom For First NASH Drug
As the global number of COVID-19 cases exceeds 500,000 for the first time, more biopharma companies throw their weight behind Gates Foundation's drug-hunting initiative.
From the general to the particular: drug developers are increasingly tailoring therapies to individuals. Driven by important advances in understanding biology as well as new tools to harness big data, industry participants expect significant progress in biopharma’s approach to the patient.
Oncologic Drugs Advisory Committee members wondered when Keytruda should be used since cystectomy can be curative and waiting could make the surgery more difficult.
Many Oncologic Drugs Advisory Committee members struggled to decide whether the data showed a clinically meaningful benefit in the proposed bladder cancer indication.
- Therapeutic Areas
- Neurology, Nervous System
- North America
- Parent & Subsidiaries
- Eisai Co. Ltd.
- Senior Management
Ivan Cheung, Chmn. & CEO
Patrick Coyle, VP, CFO
Shaji Procida, Pres. & COO
Joel W Beetsch, VP, Corp. Affairs
- Contact Info
Phone: (201) 692-1100
100 Tice Blvd.
Woodcliff Lake, NJ 07677
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.